MANNITOL 10% (mannitol) by Pfizer is osmotic activity [moa]. First approved in 1967.
Drug data last refreshed 1m ago · AI intelligence enriched 1w ago
MANNITOL 10% is an osmotic diuretic administered by injection used to reduce intracranial pressure and manage cerebral edema in acute medical and surgical settings. It works through osmotic activity, drawing fluid from tissues into the vascular space for rapid diuresis. This is a legacy small-molecule product first approved in 1967 with established clinical utility in neurocritical care.
As a mature, off-patent product facing LOE, the brand team is likely small and focused on defending market share against generic competition in hospital and ICU channels.
Osmotic Activity
Osmotic Diuretic
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
PT027 Compared to PT007 in Patients With Asthma With Mannitol-induced Acute Airway Obstruction
Mannitol-Induced Cough Challenge in Healthy Controls and Subjects With Mild Allergic Asthma
A Study Comparing Picoprep With Mannitol and Bisacodyl for Colon Cleansing in Preparation for Colonoscopy
A Safety and Efficacy Trial of Inhaled Mannitol in Adult Cystic Fibrosis Subjects
Worked on MANNITOL 10% at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on MANNITOL 10% offers exposure to hospital/acute care sales channels, formulary management, and defensive brand strategies in a stable, non-growth environment. Career progression is limited by product maturity but provides valuable experience in generic-competitive and off-patent market dynamics.